title: Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules.
abstract: BACKGROUND
  Fine-needle aspiration biopsy (FNAB) is the primary means of distinguishing benign from malignant and of guiding therapeutic intervention in thyroid nodules. However, 10% to 30% of cases with indeterminate cytology in FNAB need other diagnostic tools to refine diagnosis.
  
  
  OBJECTIVE
  We compared the pyrosequencing method with the conventional direct DNA sequencing analysis and investigated the usefulness of preoperative BRAF mutation analysis as an adjunct diagnostic tool with routine FNAB.
  
  
  METHODS
  A total of 103 surgically confirmed patients' FNA slides were recruited and DNA was extracted after atypical cells were scraped from the slides. BRAF mutation was analyzed by pyrosequencing and direct DNA sequencing.
  
  
  RESULTS
  Sixty-three (77.8%) of 81 histopathologically diagnosed malignant nodules revealed positive BRAF mutation on pyrosequencing analysis. In detail, 63 (84.0%) of 75 papillary thyroid carcinoma (PTC) samples showed positive BRAF mutation, whereas 3 follicular thyroid carcinomas, 1 anaplastic carcinoma, 1 medullary thyroid carcinoma, and 1 metastatic lung carcinoma did not show BRAF mutation. None of 22 benign nodules had BRAF mutation in both pyrosequencing and direct DNA sequencing. Out of 27 thyroid nodules classified as 'indeterminate' on cytologic examination preoperatively, 21 (77.8%) cases turned out to be malignant: 18 PTCs (including 2 follicular variant types) and 3 follicular thyroid carcinomas. Among these, 13 (61.9%) classic PTCs had BRAF mutation. None of 6 benign nodules, including 3 follicular adenomas and 3 nodular hyperplasias, had BRAF mutation. Among 63 PTCs with positive BRAF mutation detected by pyrosequencing analysis, 3 cases did not show BRAF mutation by direct DNA sequencing. Although it was not statistically significant, pyrosequencing was superior to direct DNA sequencing in detecting the BRAF mutation of thyroid nodules (P=0.25).
  
  
  CONCLUSIONS
  Detecting BRAF mutation by pyrosequencing is more sensitive, faster, and less expensive than direct DNA sequencing and is proposed as an adjunct diagnostic tool in evaluating thyroid nodules of indeterminate cytology.
authors.affiliation: Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
authors.forename: Suk Kyeong
authors.initials: SK
authors.lastname: Kim
authors.forename: Dong-Lim
authors.initials: DL
authors.lastname: Kim
authors.forename: Hye Seung
authors.initials: HS
authors.lastname: Han
authors.forename: Wan Seop
authors.initials: WS
authors.lastname: Kim
authors.forename: Seung Ja
authors.initials: SJ
authors.lastname: Kim
authors.forename: Won Jin
authors.initials: WJ
authors.lastname: Moon
authors.forename: Seo Young
authors.initials: SY
authors.lastname: Oh
authors.forename: Tae Sook
authors.initials: TS
authors.lastname: Hwang
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism / Q000556:secondary; D044963:Biopsy, Fine-Needle; D045744:Cell Line, Tumor; D004252:DNA Mutational Analysis / Q000191:economics / Q000379:methods*; D004273:DNA, Neoplasm / Q000032:analysis; D006801:Humans; D016133:Polymerase Chain Reaction; D011237:Predictive Value of Tests; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics* / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D016606:Thyroid Nodule / Q000235:genetics* / Q000378:metabolism / Q000473:pathology
chemical_list: D004273:DNA, Neoplasm; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf